Answers are grounded in this paper and cite their sources.
A series of novel maleimide-based inhibitors of protein kinase C (PKC) were designed, synthesized, and evaluated. AEB071 (1) was found to be a potent, selective inhibitor of classical and novel PKC isotypes. 1 is a highly efficient immunomodulator, acting via inhibition of early T cell activation. The binding mode of maleimides to PKCs, proposed by molecular modeling, was confirmed by X-ray analysis of 1 bound in the active site of PKCalpha.
No takes yet. Share an insight, caveat, or question.
Wagner et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: